28533317|t|Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use
28533317|a|Millions of individuals have used illicit anabolic-androgenic steroids (AAS), but the long-term cardiovascular associations of these drugs remain incompletely understood. Using a cross-sectional cohort design, we recruited 140 experienced male weightlifters 34 to 54 years of age, comprising 86 men reporting ≥2 years of cumulative lifetime AAS use and 54 nonusing men. Using transthoracic echocardiography and coronary computed tomography angiography, we assessed 3 primary outcome measures: left ventricular (LV) systolic function (left ventricular ejection fraction), LV diastolic function (early relaxation velocity), and coronary atherosclerosis (coronary artery plaque volume). Compared with nonusers, AAS users demonstrated relatively reduced LV systolic function (mean ± SD left ventricular ejection fraction = 52±11% versus 63±8%; P<0.001) and diastolic function (early relaxation velocity = 9.3±2.4 cm/second versus 11.1±2.0 cm/second; P<0.001). Users currently taking AAS at the time of evaluation (N=58) showed significantly reduced LV systolic (left ventricular ejection fraction = 49±10% versus 58±10%; P<0.001) and diastolic function (early relaxation velocity = 8.9±2.4 cm/second versus 10.1±2.4 cm/second; P=0.035) compared with users currently off - drug (N=28). In addition, AAS users demonstrated higher coronary artery plaque volume than nonusers (median [interquartile range] 3 [0, 174] mL(3) versus 0 [0, 69] mL(3); P=0.012). Lifetime AAS dose was strongly associated with coronary atherosclerotic burden (increase [95% confidence interval] in rank of plaque volume for each 10- year increase in cumulative duration of AAS use: 0.60 SD units [0.16-1.03 SD units]; P=0.008). Long-term AAS use appears to be associated with myocardial dysfunction and accelerated coronary atherosclerosis. These forms of AAS - associated adverse cardiovascular phenotypes may represent a previously underrecognized public-health problem.
28533317	0	14	Cardiovascular	T029	C3887460
28533317	15	23	Toxicity	T037	C0600688
28533317	27	34	Illicit	T169	C0332266
28533317	35	62	Anabolic-Androgenic Steroid	T109	C0038317
28533317	63	66	Use	T169	C0457083
28533317	67	75	Millions	T081	C1881839
28533317	79	90	individuals	T098	C0237401
28533317	101	108	illicit	T169	C0332266
28533317	109	137	anabolic-androgenic steroids	T109	C0038317
28533317	139	142	AAS	T109	C0038317
28533317	153	162	long-term	T079	C0443252
28533317	163	177	cardiovascular	T029	C3887460
28533317	178	190	associations	T080	C0439849
28533317	200	205	drugs	T121	C1254351
28533317	213	225	incompletely	T080	C0205257
28533317	226	236	understood	T041	C0162340
28533317	246	275	cross-sectional cohort design	T062	C0035171
28533317	280	289	recruited	T052	C2949735
28533317	294	305	experienced	T041	C0596545
28533317	306	324	male weightlifters	T098	C0025266
28533317	334	346	years of age	T079	C1510829
28533317	348	358	comprising	T052	C2700400
28533317	362	365	men	T098	C0025266
28533317	366	375	reporting	T058	C0700287
28533317	376	384	≥2 years	T033	C3843647
28533317	388	398	cumulative	T080	C1511559
28533317	399	407	lifetime	T079	C4071830
28533317	408	411	AAS	T109	C0038317
28533317	412	415	use	T169	C0457083
28533317	423	431	nonusing	T169	C0205245
28533317	432	435	men	T098	C0025266
28533317	443	473	transthoracic echocardiography	T060	C0430462
28533317	478	518	coronary computed tomography angiography	T060	C1634617
28533317	523	531	assessed	T052	C1516048
28533317	534	558	primary outcome measures	T080	C3274433
28533317	560	599	left ventricular (LV) systolic function	T042	C0080310
28533317	601	635	left ventricular ejection fraction	T201	C0428772
28533317	638	659	LV diastolic function	T042	C0080310
28533317	661	666	early	T079	C1279919
28533317	667	677	relaxation	T052	C0035028
28533317	678	686	velocity	T081	C0439830
28533317	693	717	coronary atherosclerosis	T047	C0010054
28533317	719	734	coronary artery	T023	C0205042
28533317	735	741	plaque	T033	C0332461
28533317	742	748	volume	T081	C0449468
28533317	751	759	Compared	T052	C1707455
28533317	765	773	nonusers	T098	C1257890
28533317	775	778	AAS	T109	C0038317
28533317	779	784	users	T101	C0338666
28533317	798	808	relatively	T080	C0205345
28533317	809	816	reduced	T080	C0392756
28533317	817	837	LV systolic function	T042	C0080310
28533317	839	843	mean	T081	C0444504
28533317	846	848	SD	T081	C0871420
28533317	849	883	left ventricular ejection fraction	T201	C0428772
28533317	920	938	diastolic function	T042	C0080310
28533317	940	945	early	T079	C1279919
28533317	946	956	relaxation	T052	C0035028
28533317	957	965	velocity	T081	C0439830
28533317	976	985	cm/second	T081	C0439392
28533317	1002	1011	cm/second	T081	C0439392
28533317	1023	1028	Users	T101	C0338666
28533317	1029	1038	currently	T079	C0521116
28533317	1039	1045	taking	T058	C1515187
28533317	1046	1049	AAS	T109	C0038317
28533317	1065	1075	evaluation	T052	C1516048
28533317	1090	1111	significantly reduced	T081	C4055638
28533317	1112	1123	LV systolic	T042	C0080310
28533317	1125	1159	left ventricular ejection fraction	T201	C0428772
28533317	1197	1215	diastolic function	T042	C0080310
28533317	1217	1222	early	T079	C1279919
28533317	1223	1233	relaxation	T052	C0035028
28533317	1234	1242	velocity	T081	C0439830
28533317	1253	1262	cm/second	T081	C0439392
28533317	1279	1288	cm/second	T081	C0439392
28533317	1299	1307	compared	T052	C1707455
28533317	1313	1318	users	T101	C0338666
28533317	1319	1328	currently	T079	C0521116
28533317	1329	1332	off	T080	C1518543
28533317	1335	1339	drug	T121	C1254351
28533317	1348	1359	In addition	T169	C0332287
28533317	1361	1364	AAS	T109	C0038317
28533317	1365	1370	users	T101	C0338666
28533317	1384	1390	higher	T080	C0205250
28533317	1391	1406	coronary artery	T023	C0205042
28533317	1407	1413	plaque	T033	C0332461
28533317	1414	1420	volume	T081	C0449468
28533317	1426	1434	nonusers	T098	C1257890
28533317	1436	1442	median	T081	C0876920
28533317	1444	1463	interquartile range	T081	C1711350
28533317	1516	1524	Lifetime	T079	C4071830
28533317	1525	1528	AAS	T109	C0038317
28533317	1529	1533	dose	T081	C0178602
28533317	1538	1562	strongly associated with	T080	C0332281
28533317	1563	1587	coronary atherosclerotic	T047	C0010054
28533317	1588	1594	burden	T078	C2828008
28533317	1596	1604	increase	T169	C0442805
28533317	1610	1629	confidence interval	T081	C0009667
28533317	1642	1648	plaque	T033	C0332461
28533317	1649	1655	volume	T081	C0449468
28533317	1660	1664	each	T081	C1457900
28533317	1669	1673	year	T079	C0439234
28533317	1674	1682	increase	T169	C0442805
28533317	1686	1696	cumulative	T080	C1511559
28533317	1697	1705	duration	T079	C0449238
28533317	1709	1712	AAS	T109	C0038317
28533317	1713	1716	use	T169	C0457083
28533317	1723	1725	SD	T081	C0871420
28533317	1726	1731	units	T081	C1519795
28533317	1743	1745	SD	T081	C0871420
28533317	1746	1751	units	T081	C1519795
28533317	1764	1773	Long-term	T079	C0443252
28533317	1774	1777	AAS	T109	C0038317
28533317	1778	1781	use	T169	C0457083
28533317	1796	1811	associated with	T080	C0332281
28533317	1812	1834	myocardial dysfunction	T046	C0340515
28533317	1839	1850	accelerated	T169	C0521110
28533317	1851	1875	coronary atherosclerosis	T047	C0010054
28533317	1883	1888	forms	T080	C0348078
28533317	1892	1895	AAS	T109	C0038317
28533317	1898	1908	associated	T080	C0332281
28533317	1909	1916	adverse	T046	C0879626
28533317	1917	1931	cardiovascular	T029	C3887460
28533317	1932	1942	phenotypes	T032	C0031437
28533317	1947	1956	represent	T052	C1882932
28533317	1959	1969	previously	T079	C0205156
28533317	1986	2007	public-health problem	T033	C1398682